Cowen & Co. Assigns a Hold Rating on Regeneron

By Austin Angelo

In a report released today, Phil Nadeau from Cowen & Co. assigned a Hold rating to Regeneron (NASDAQ: REGN), with a price target of $450. The company’s shares opened today at $338.80, close to its 52-week low of $319.50.

According to, Nadeau is a 5-star analyst with an average return of 14.2% and a 56.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Rhythm Pharmaceuticals Inc, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Regeneron is Moderate Buy and the average price target is $454.21, representing a 34.1% upside.

In a report issued on January 24, J.P. Morgan also maintained a Hold rating on the stock with a $457 price target.

The company has a one-year high of $543.55 and a one-year low of $319.50. Currently, Regeneron has an average volume of 869.2K.

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of REGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases. It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.